Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Pfizer (PFE) for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company’s leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver. Under the agreement, Pfizer has granted Madrigal an exclusive global license to develop, manufacture and commercialize ervogastat, as well as rights to two additional early-stage MASH pipeline assets. Pfizer received an upfront payment of $50 million USD, which will be reflected in Madrigal’s fourth quarter 2025 expenses, and is eligible for additional payments if certain milestones are achieved, as well as royalties on net sales.